Lungs News and Research

RSS

Ukraine uses EDAPS Tax Stamp System to control illicit sales of tobacco products

The most recent edition of the authoritative Tobacco Atlas, released by the American Cancer Society and World Lung Foundation, ranks nations on their success in combating illegal sales of cigarettes and tobacco products.

31 Mar 2010

High radon levels in residential buildings can cause lung cancer

About 1900 deaths from lung cancer per year in Germany are due to radon within residential buildings. This was the conclusion reached in the current edition of Deutsches -rzteblatt International by Klaus Schmid of the University of Erlangen-Nuremberg and his coauthors (Dtsch Arztebl Int 2010; 107(11): 181-6).

31 Mar 2010

Hsp90 inhibitors may help fight cardiovascular disease, say researchers

New drugs that are helping fight a multi-front war on cancer may do the same for cardiovascular disease, Medical College of Georgia researchers said.

31 Mar 2010

CTRC initiates patient enrolment in U.S. Phase 2 clinical trial of REOLYSIN

Oncolytics Biotech Inc. announced today that the Cancer Therapy & Research Center at the University of Texas Health Science Center has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with carboplatin and paclitaxel in patients with squamous cell carcinoma of the lungs.

30 Mar 2010

Two Phase I studies of Stedivaze demonstrate safety in patients with asthma and COPD

Clinical Data, Inc., today announced results from two Phase I studies of Stedivaze™ (apadenoson), which demonstrated that Stedivaze was safe and well tolerated in patients with asthma and chronic obstructive pulmonary disease (COPD). Stedivaze is a potent and highly selective agonist of the adenosine A2A receptor subtype in development as a pharmacologic stress agent for myocardial perfusion imaging (MPI).

30 Mar 2010

Mutations in gene protecting body leads to development of cancer

An important gene that normally protects the body against cancer can itself cause a variety of cancers depending on the specific mutation that damages it, according to a new study by investigators at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James).

30 Mar 2010

Systemic treatment of microRNA therapeutic targeting miR-10b inhibits breast cancer metastasis

Regulus Therapeutics Inc. today announced the publication of new results in the journal Nature Biotechnology by Regulus scientists and collaborators. The new study demonstrated that systemic treatment of a microRNA therapeutic targeting microRNA-10b in tumor-bearing mice inhibits breast cancer metastasis. Cancer-related metastasis is a major cause of mortality and current cancer treatments have limited utility suppressing the metastatic spread of cancer cells. microRNA therapeutics targeting miR-10b represent a promising approach for the discovery and development of a novel anti-metastatic agent.

30 Mar 2010

Research challenges current thinking about TB bacterium

Two new tuberculosis studies by UT Southwestern Medical Center researchers provide good news and bad news about the bacterium that infects nearly a third of the world's population and a disease that kills nearly 2 million people each year.

30 Mar 2010

Positive results from Pearl Therapeutics' Phase 1 study of inhaled combination bronchodilator for COPD

Pearl Therapeutics Inc., a company developing clinically differentiated combination therapies for the treatment of highly prevalent chronic respiratory diseases, today announced positive results from a Phase 1 safety and pharmacokinetics study of PT003, its lead combination therapeutic for the treatment of chronic obstructive pulmonary disease (COPD). Based on these results, and previously announced positive results from Phase 2a studies of PT003's individual components, the company has advanced PT003 into a Phase 2b trial.

29 Mar 2010

Enrollment complete in Gemin X Pharmaceuticals' Phase 2 clinical trial of obatoclax for SCLC

Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today announced the completion of patient enrollment in a Phase 2 clinical trial of the Company's lead product candidate obatoclax (GX15-070) for the treatment of extensive-stage small cell lung cancer (SCLC). The trial is designed to evaluate the efficacy and safety of obatoclax, a novel pan Bcl-2 inhibitor, in combination with standard chemotherapy for the first-line treatment of patients with SCLC.

29 Mar 2010

Inovio Biomedical's total revenue increased to $2.6M for quarter ended December 31, 2009

Inovio Biomedical Corporation today reported financial results for the quarter and year ended December 31, 2009.

29 Mar 2010

FT and GGT enzymes can be promising targets for treatment of lung cancer

A research team at the Sahlgrenska Academy at the University of Gothenburg, Sweden, has shown in a study that two closely related enzymes could be targets for the treatment of lung cancer. The discovery was made when the researchers blocked the production of the two enzymes in transgenic mice. This resulted in inhibition of cell growth, fewer tumours and greater survival among the mice.

29 Mar 2010

TB-causing bacteria can hijack fat metabolism to drive progression of the disease

The factors instrumental in triggering latent tuberculosis infection to progress into active disease have long remained elusive to researchers. New insight into the mystery is provided by Professor David Russell, speaking at the Society for General Microbiology's spring meeting in Edinburgh today. His work could help develop innovative strategies for treating the disease.

29 Mar 2010

New scientific discoveries show that Canadian maple syrup can be good for health

The Federation of Quebec Maple Syrup Producers is pleased to report on two new scientific discoveries which show that Canadian maple syrup can be good for you. These studies build on recent findings on the nutritional value of maple products, which have revealed both the antioxidant properties of maple syrup as well as the discovery of substantial quantities of abscisic acid.

27 Mar 2010

Lymph node radiotherapy well-tolerated after mastectomy or breast conserving surgery

In patients with early breast cancer, giving radiotherapy to the lymph nodes located behind the breast bone and above the collar bone is well-tolerated, after mastectomy or breast conserving surgery, a radiation oncologist will tell delegates at the seventh European Breast Cancer Conference (EBCC7) today (Saturday 27 March).

27 Mar 2010

Agent Orange exposure: VA adds three new illnesses to list of health problems

Well over 100,000 Veterans exposed to herbicides while serving in Vietnam and other areas will have an easier path to qualify for disability pay under a proposed regulation published by the Department of Veterans Affairs (VA) that adds three new illnesses to the list of health problems found to be related to Agent Orange and other herbicide exposures.

27 Mar 2010

Genome sequencing of tumors biopsied from women with invasive breast cancer

Tumors biopsied from women with invasive breast cancer are having their genomes sequenced in an attempt to develop a DNA profile that one day may identify ahead of time the patients who will most likely respond to chemotherapy with an aromatase inhibitor. Aromatase inhibitors are a class of chemotherapeutic agents that block the production of estrogen in postmenopausal women.

27 Mar 2010

Research Roundup: Middle class health cost burden, disparities and cancer, summary of new health law

The Growing Financial Burden Of Health Care: National And State Trends, 2001-2006 - This paper examines the ratio of total out-of-pocket spending for health care and insurance to total family income, using data from the Medical Expenditure Panel Surveys for 2001-2006.

26 Mar 2010

Lung transplant patients may one day benefit from synthetic peptide, researchers report

Lung transplant patients may one day benefit from a synthetic peptide that mimics the body's natural ability to reduce excess fluid accumulation, Medical College of Georgia researchers report.

26 Mar 2010

Bevacizumab/paclitaxel/carboplatin regimen attains gold-standard status for treatment of non-small-cell lung cancer

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the bevacizumab (Genentech/Roche/Chugai's Avastin)/paclitaxel (Bristol-Myers Squibb's Taxol, generics)/carboplatin (Bristol-Myers Squibb's Paraplatin, generics) regimen will remain Decision Resources' proprietary clinical gold standard for the treatment of advanced non-small-cell lung cancer through 2018.

26 Mar 2010

Lungs News and Research

Ukraine uses EDAPS Tax Stamp System to control illicit sales of tobacco products

High radon levels in residential buildings can cause lung cancer

Hsp90 inhibitors may help fight cardiovascular disease, say researchers

CTRC initiates patient enrolment in U.S. Phase 2 clinical trial of REOLYSIN

Two Phase I studies of Stedivaze demonstrate safety in patients with asthma and COPD

Mutations in gene protecting body leads to development of cancer

Systemic treatment of microRNA therapeutic targeting miR-10b inhibits breast cancer metastasis

Research challenges current thinking about TB bacterium

Positive results from Pearl Therapeutics' Phase 1 study of inhaled combination bronchodilator for COPD

Enrollment complete in Gemin X Pharmaceuticals' Phase 2 clinical trial of obatoclax for SCLC

Inovio Biomedical's total revenue increased to $2.6M for quarter ended December 31, 2009

FT and GGT enzymes can be promising targets for treatment of lung cancer

TB-causing bacteria can hijack fat metabolism to drive progression of the disease

New scientific discoveries show that Canadian maple syrup can be good for health

Lymph node radiotherapy well-tolerated after mastectomy or breast conserving surgery

Agent Orange exposure: VA adds three new illnesses to list of health problems

Genome sequencing of tumors biopsied from women with invasive breast cancer

Research Roundup: Middle class health cost burden, disparities and cancer, summary of new health law

Lung transplant patients may one day benefit from synthetic peptide, researchers report

Bevacizumab/paclitaxel/carboplatin regimen attains gold-standard status for treatment of non-small-cell lung cancer

The ultimate guide to lung research tools and protocols eBook

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Latest News